Latest Retail Entitlement Offer News

Eagers Automotive has finalized its majority acquisition of CanadaOne Auto, positioning itself among the world’s largest automotive retail groups with combined pro-forma revenue nearing A$19 billion.

Tamboran Resources has closed its retail entitlement offer, adding A$24.8 million to a total equity raise of A$282.6 million to fund expanded drilling and development in the Beetaloo Basin.

Syrah Resources delivered a record 24kt graphite production at Balama and secured US$72 million in equity to support medium-term ramp-up and Vidalia commercialisation, navigating a complex US trade environment.

PYC Therapeutics fortified its balance sheet by $600 million and progressed key RNA therapeutic trials in Q1 2026, setting the stage for pivotal clinical data and regulatory submissions.

PYC Therapeutics has gained Orphan Drug Designation from the European Medicines Agency for its VP-001 candidate targeting Retinitis Pigmentosa type 11, enhancing its regulatory and commercial pathway in Europe.

NEXTDC has launched the retail tranche of its A$1.5 billion fully underwritten entitlement offer at A$12.70 per share, aiming to back accelerated data centre capacity growth amid unprecedented contracted utilisation.

Eagers Automotive delivered a record $13 billion revenue in 2025, boosted market share in new and New Energy Vehicles, and secured landmark global partnerships to fuel future growth.

Syrah Resources has closed its retail entitlement offer, securing A$61 million and pushing total equity raised to A$104 million. AustralianSuper’s stake will approach half the company as Syrah prepares to fund key projects and advance strategic funding talks.

KMD Brands has wrapped up a fully underwritten entitlement offer and placement, raising NZ$65.3 million to reduce net debt and shore up its balance sheet ahead of executing its growth plans.

KMD Brands has secured NZ$11 million from its retail entitlement offer, with a 52% participation rate. The company now moves to clear a 169 million share shortfall through a retail bookbuild, while shares remain halted ahead of trading resumption.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing of its investigational drug PYC-001 for Autosomal Dominant Optic Atrophy from single to multiple doses, marking a key step in its clinical development.

Tamboran Resources Corporation is extending its capital raise with a partially underwritten retail entitlement offer worth up to A$27 million, following a US$163 million institutional and public offering. The proceeds will accelerate drilling and resource delineation in the Beetaloo Basin, aiming to underpin first gas sales in 2026.